29 reports of this reaction
2.6% of all MENTHOL, METHYL SALICYLATE reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu Pharmaceutical Co., Inc.. There are 29 FDA adverse event reports linking MENTHOL, METHYL SALICYLATE to DYSPNOEA. This represents approximately 2.6% of all 1,107 adverse event reports for this drug.
Patients taking MENTHOL, METHYL SALICYLATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for MENTHOL, METHYL SALICYLATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 29 FDA reports for MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.6% of all adverse event reports for MENTHOL, METHYL SALICYLATE, making it a notable side effect.
If you experience dyspnoea while taking MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.